Synthesis of Two Stereoisomers of Potentially Bioactive 13,19,20-Trihydroxy Derivative of Docosahexaenoic Acid

Narihito Ogawa; Shinsaku Sone; Song Hong; Yan Lu; Yuichi Kobayashi

doi:10.1055/s-0040-1706415

Synlett, Table of Contents

Synlett 2020; 31(17): 1735-1739
DOI: 10.1055/s-0040-1706415

letter

Synthesis of Two Stereoisomers of Potentially Bioactive 13,19,20-Trihydroxy Derivative of Docosahexaenoic Acid

Narihito Ogawa∗

^aDepartment of Applied Chemistry, Meiji University, 1-1-1, Higashimita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan Email: narihito@meiji.ac.jp

,

Shinsaku Sone

^aDepartment of Applied Chemistry, Meiji University, 1-1-1, Higashimita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan Email: narihito@meiji.ac.jp

,

Song Hong

^bNeuroscience Center of Excellence, Louisiana State University, Health Sciences Center, 2020 Gravier St., New Orleans, LA 70112, USA

^cDepartment of Ophthalmology, Louisiana State University, Health Sciences Center, New Orleans, LA 70112, USA

,

Yan Lu

^bNeuroscience Center of Excellence, Louisiana State University, Health Sciences Center, 2020 Gravier St., New Orleans, LA 70112, USA

,

Yuichi Kobayashi

^dMeiji University, Organization for the Strategic Coordination of Research and Intellectual Properties, 1-1-1 Higashimita, Tama-ku, Kawasaki, Kanagawa 214-8571, Japan

› Author Affiliations

Abstract

All articles of this category

Abstract

The C16–C22 fragment with the acetylene terminus was constructed through the asymmetric dihydroxylation of the corresponding olefin, while the 15-iodo-olefin corresponding to the C11–C15 part was prepared via the asymmetric transfer hydrogenation of the corresponding acetylene ketone followed by hydrozirconation/iodination. Both pieces were joined by a Sonogashira coupling, and the product was further converted into the title compound via a Wittig reaction with the remaining C1–C10 segment and Boland reduction using Zn with TMSCl.

Key words

DHA metabolite - trihydroxylated DHA - organic synthesis - enyne - Boland reduction - TMSCl - Hansen protocol

Full Text

References

References and Notes

1a Pham TL, Kakazu AH, He J, Jun B, Bazan NG, Bazan HE. P. Sci. Rep. 2020; 10: 4582
1b Saini RK, Keum Y.-S. Life Sci. 2018; 203: 255
1c Basil MC, Levy BD. Nat. Rev. Immunol. 2016; 16: 51
1d Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N. Biochim. Biophys. Acta 2015; 1851: 397
1e Kuhn H, Banthiya S, van Leyen K. Biochim. Biophys. Acta 2015; 1851: 308
1f Isobe Y, Arita M. J. Clin. Biochem. Nutr. 2014; 55: 79
1g Serhan CN, Nicos A, Petasis NA. Chem. Rev. 2011; 111: 5922
1h Lukiw WJ, Cui J.-G, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. J. Clin. Invest. 2005; 115: 2774
1i Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN. J. Exp. Med. 2005; 201: 713
1j Bazan NG. Mol. Neurobiol. 2005; 31: 219
1k Bazan NG. Brain Pathol. 2005; 15: 159
1l Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG. J. Biol. Chem. 2003; 278: 43807

2a Lu Y, Tian H, Hong S. J. Lipid Res. 2010; 51: 923
2b Tian H, Lu Y, Shah SP, Hong S. J. Cell. Biochem. 2010; 111: 266

3a Tian H, Lu Y, Shah SP, Wang Q, Hong S. Stem Cells Dev. 2012; 21: 1187
3b Tian H, Lu Y, Shah SP, Hong S. Am. J. Pathol. 2011; 179: 1780
3c Tian H, Lu Y, Shah SP, Hong S. J. Biol. Chem. 2011; 286: 4443

4 Nishimura K, Sakaguchi T, Nanba Y, Suganuma Y, Morita M, Hong S, Lu Y, Jun B, Bazan NG, Arita M, Kobayashi Y. J. Org. Chem. 2018; 83: 154
5 Hong S, Lu Y, Tian H, Alapure BV, Wang Q, Bunnell BA, Laborde JM. Chem. Biol. 2014; 21: 1318
6 Hong S, Lu Y, Morita M, Saito S, Kobayashi Y, Jun B, Bazan NG, Xu X, Wang Y. Synlett 2019; 30: 343

7a Roy J, Watson JE, Hong IS, Fan TM, Das A. J. Med. Chem. 2018; 61: 5569
7b McDougle DR, Watson JE, Abdeen AA, Adili R, Caputo MP, Krapf JE, Johnson RW, Kilian KA, Holinstat M, Das A. Proc. Natl. Acad. Sci. U.S.A. 2017; 114: E6034
7c Shearer GC, Harris WS, Pederson TL, Newman JW. J. Lipid Res. 2010; 51: 2074

8a Pickens CA, Sordillo LM, Zhang C, Fenton JI. Metab. Clin. Exp. 2017; 70: 177
8b Tajima Y, Ishikawa M, Maekawa K, Murayama M, Senoo Y, Nishimaki-Mogami T, Nakanishi H, Ikeda K, Arita M, Taguchi R, Okuno A, Mikawa R, Niida S, Takikawa O, Saito Y. Lipids Health Dis. 2013; 12: 68
8c Morisseau C, Inceoglu B, Schmelzer K, Tsai H.-J, Jinks SL, Hegedus CM, Hammock BD. J. Lipid Res. 2010; 51: 3481
8d Oliw EH, Sprecher HW. Biochim. Biophys. Acta 1991; 1086: 287
8e VanRollins M, Baker RC, Sprecher HW, Murphy RC. J. Biol. Chem. 1984; 259: 5776

9 Arita M, Arai H, Isobe Y, Kubota T. WO2012023254 A1, 2012
10 Mortimer M, Järving R, Brash AR, Samel N, Järving I. Arch. Biochem. Biophys. 2006; 445: 147

11a Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B, Connolly ES, Solomon R, Jones DM, Heyer EJ, Spite M, Tabas I. Nat. Commun. 2016; 7: 12859
11b Hong S, Gronert K, Devchand PR, Moussignac R.-L, Serhan CN. J. Biol. Chem. 2003; 278: 14677
11c Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, Moussignac R.-L. J. Exp. Med. 2002; 196: 1025

12 Kubota T, Arita M, Isobe Y, Iwamoto R, Goto T, Yoshioka T, Urabe D, Inoue M, Arai H. FASEB J. 2014; 28: 586

13a Wang C, Liu W, Yao L, Zhang X, Zhang X, Ye C, Jiang H, He J, Zhu Y, Ai D. Br. J. Pharmacol. 2017; 174: 2358
13b Coffa G, Hill EM. Lipids 2000; 35: 1195
13c Hawkins DJ, Brash AR. J. Biol. Chem. 1987; 262: 7629

14 A similar compound would be derived from n-3 docosapentaenoic acid, see: Vik A, Dalli J, Hansen TV. Bioorg. Med. Chem. Lett. 2017; 27: 2259

15a Young UJ, Miklossy G, Chai X, Wongwiwatthananukit S, Toyama O, Songsak T, Turkson J, Chang LC. Fitoterapia 2014; 93: 194
15b Blée E, Schuber F. Eur. J. Biochem. 1995; 230: 229
15c Morris LJ, Crouchman ML. Lipids 1972; 7: 372
15d Morris LJ, Crouchman ML. Lipids 1969; 4: 50

16 Kolb HC, VanNieuwenhze MS, Sharpless KB. Chem. Rev. 1994; 94: 2483
17 Matsumura K, Hashiguchi S, Ikariya T, Noyori R. J. Am. Chem. Soc. 1997; 119: 8738
18 Spinella A, Caruso T, Martino M, Sessa C. Synlett 2001; 1971
19 Caruso T, Spinella A. Tetrahedron: Asymmetry 2002; 13: 2071
20 Ogawa N, Tojo T, Kobayashi Y. Tetrahedron Lett. 2014; 55: 2738

21a Saito S, Nanba Y, Morita M, Kobayashi Y. Synlett 2019; 30: 1085
21b Hartmann O, Kalesse M. Org. Lett. 2012; 14: 3064

22a Kiyotsuka Y, Igarashi J, Kobayashi Y. Tetrahedron Lett. 2002; 43: 2725
22b Huang Z, Negishi E. Org. Lett. 2006; 8: 3675

23a Akoto CO, Rainier JD. Synthesis 2019; 51: 3529
23b Chakraborty TK, Purkait S, Das S. Tetrahedron 2003; 59: 9127

24 Brown CA, Ahuja VK. J. Chem. Soc., Chem. Commun. 1973; 553
25 The use of 1 equiv of HMPA caused the elimination of the TBDPS-oxy group.
26 Mohamed YM. A, Hansen TV. Tetrahedron 2013; 69: 3872
27 Boland W, Schroer N, Sieler C. Helv. Chim. Acta 1987; 70: 1025
28 Determined by ¹H NMR spectroscopy and R _f values (0.60 and 0.33 for the byproduct and 25 (hexane/EtOAc = 1:2).
29 Dayaker G, Durand T, Balas L. Chem. Eur. J. 2014; 20: 2879 ; see the Supporting Information on page S35
30 To an argon-bubbled suspension of Zn powder (4.30 g, 65.8 mmol) in H₂O (20 mL) were added Cu(OAc)₂ (436 mg, 2.40 mmol) and, after 20 min, AgNO₃ (442 mg, 2.60 mmol). The suspension was stirred for 45 min and filtered by suction, and the remaining solids were washed with H₂O, MeOH, acetone, and Et₂O, sequentially. A solution of triol 5aa (129 mg, 0.330 mmol) in H₂O/MeOH (1:1, 20 mL) was added to the above solids. Subsequently, TMSCl (0.410 mL, 3.28 mmol) was added. The mixture was stirred at rt for 18 h and filtered through a pad of Celite. The filtrate was concentrated, and the residue was purified first by chromatography on silica gel (hexane/EtOAc) and second by recycling HPLC (LC-Forte/R equipped with YMC-Pack SIL-60, ø 20 × 250 mm, hexane/EtOAc 30:70, 25 mL/min) to afford methyl ester 25 (104 mg, 81%) as a colorless liquid: R_f = 0.22 (hexane/EtOAc = 1:2); [α]_D ²¹ –2.3 (c 1.0, CHCl₃). IR (neat): 3480, 1733, 1652, 759 cm^–1. ¹H NMR (400 MHz, CDCl₃): δ = 0.99 (t, J = 7.4 Hz, 3 H), 1.44–1.66 (m, 2 H), 1.77 (br s, 1 H), 2.22–2.52 (m, 10 H), 2.77–2.90 (m, 4 H), 3.40 (dt, J = 8.4, 4.2 Hz, 1 H), 3.53 (q, J = 5.8 Hz, 1 H), 3.68 (s, 3 H), 4.25 (q, J = 6.0 Hz, 1 H), 5.31–5.60 (m, 7 H), 5.77 (dd, J = 15.2, 6.0 Hz, 1 H), 6.16 (t, J = 11.2 Hz, 1 H), 6.55 (dd, J = 15.2, 11.2 Hz, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ = 10.1, 22.9, 25.7, 25.9, 26.6, 32.3, 34.1, 35.4, 51.7, 71.9, 73.5, 75.1, 125.0, 125.3, 127.5, 127.9, 128.0, 128.3, 129.4, 130.8, 131.2, 136.5, 173.8. HRMS (FD): m/z calcd for C₂₃H₃₆O₅ [M]⁺: 392.25627; found: 392.25781.

Supplementary Material

Supporting Information